Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- (Currently amended) A method for detecting the presence or level of 1. alkylated cytosine in a sample of genomic or mitochondrial double stranded DNA from an individual, the method comprising:
 - (a) obtaining a sample of the double stranded DNA from the individual;
 - (b) converting at least one region of the double stranded DNA to single stranded DNA;
 - (c) reacting a target region of the single stranded DNA from step (b) with at least one enzyme, the enzyme differentially modifying alkylated cytosine and cytosine present in the single stranded DNA; and
 - (d) determining the level of enzymatic modification of the target region by the enzyme.
- (Original) A method according to claim 1 wherein the single stranded DNA is reacted with the enzyme under conditions such that the enzyme reacts substantially only with either alkylated cytosine or cytosine in the single stranded DNA but not both.

Attorney Docket No. 102782.60031US

3. (Original) A method according to claim 1 wherein the enzyme is capable

of reacting substantially with only one of alkylated cytosine or cytosine in the

single stranded DNA.

(Original) A method according to claim 1 wherein the conversion of the

region of the double stranded DNA to the single stranded DNA comprises at

least partially separating the two strands of the double stranded DNA.

5. (Original) A method according to claim 4 wherein one or more strand

displacing probes are utilised to at least partially separate the two strands of the

double stranded DNA.

6. (Original) A method according to claim 5 wherein the or each strand

displacing probe is independently selected from the group consisting of nucleic

acid analogue probes, PNA containing probes, LNA containing probes, PNA

probes and LNA probes.

(Original) A method according to claim 4 further comprising inhibiting

annealing of the two strands of the double stranded DNA together once they

have been separated to facilitate access to the target region by the enzyme.

Page 8 of 25

Attorney Docket No. 102782.60031US

8. (Original) A method according to claim 7 further comprising hybridising

at least one probe with a strand of the double stranded DNA following separation

of the two strands to thereby inhibit the annealing of the two strands together.

9. (Original) A method according to claim 8 wherein the at least one probe

is independently selected from the group consisting of sense probes, looping

probes, antisense probes and mixtures thereof.

10. (Original) A method according to claim 8 wherein at least two said

probes are hybridised with the strand of the double stranded DNA, one of the

probes hybridising with a region of the strand downstream of the target region

and a further of the probes hybridising with a region of the strand upstream of

the target region.

11. (Original) A method according to claim 8 wherein the probe hybridises

with upstream and downstream regions of the strand which flank the target

region such that a loop or bubble which incorporates the target region is formed

in the strand.

Page 9 of 25

- 12. (Original) A method according to claim 8 wherein the probe hybridises with the strand of the double stranded DNA either side of the target region and the probe has a middle region of non-complementary sequence that does not hybridise with the target region such that a loop or bubble incorporating the target region is formed in the strand.
- 13. (Original) A method according to claim 12 wherein the middle region of the probe incorporates inverted repeats that hybridise together following hybridisation of the probe with the strand of the double stranded DNA.
- 14. (Original) A method according to claim 1 wherein the determination of the level of enzymatic modification of the single stranded DNA comprises analysing for sequence variations arising from the enzymatic modification of the target region of the single stranded DNA by the enzyme.
- 15. (Original) A method according to claim 14 wherein the determination of the level of enzymatic modification comprises subjecting the target region of the single stranded DNA to an amplification process involving thermocycling and primers to obtain an amplified product, and analysing the amplified product for sequence variations.

- 16. (Original) A method according to claim 15 wherein the analysis of the amplified product comprises subjecting the amplified product to a technique selected from the group consisting of nucleic acid sequencing, polymerase chain reaction techniques, restriction enzyme digests and techniques involving the use of probes that bind to specific nucleic acid sequences.
- 17. (Original) A method according to claim 16 wherein the analysis of the amplified product comprises subjecting the amplified product to a polymerase chain reaction technique.
- 18. (Original) A method according to claim 1 wherein the at least one enzyme deaminates alkylated cytosine or cytosine in the target region of the single stranded DNA.
- 19. (Currently amended) A method according to claim 1 wherein a combination of different said enzymes are employed to differentially modify alkylated cytosine and cytosine in the target region.
- 20. (Original) A method according to claim 1 wherein the or each enzyme is independently a deaminase enzyme or a catalytic fragment, variant, homologue, or a modified form or mutant form thereof, having deaminase activity of the enzyme.

Serial No. 10/563,195 Reply to Office Action Mailed: June 20, 2008 Attorney Docket No. 102782,60031US

- (Currently amended) A method according to claim 20, wherein the
 enzyme is selected from the group consisting of ApoBRe, AID, and AID
 Apolipoprotein B mRNA editing enzyme Activation Induced Cytidine
 Deaminase, and Activation Induced Cytidine Deaminase mutant R35E/R36D.
- 22. (Original) A method according to claim 1 comprising detecting the presence or level of alkylated cytosine in a gene or a non-coding region of a gene, or a fragment thereof.
- (Original) A method according to claim 22 comprising detecting the presence or level of alkylated cytosine in a 5'untranslated region of a gene.
- (Original) A method according to claim 23 wherein the level of alkylated cytosine comprises hypermethylation.
- (Original) A method according to claim 23 wherein the level of alkylated cytosine comprises hypomethylation.
- 26. (Currently amended) A method according to claim 23 wherein the gene is selected from the group consisting of p16 Cyclin-dependent kinase inhibitor 2A. E-cadherin, the VLH gene, BRCA1, p15, hMLH1, ER, HIC1, MDG1 the vonHippel Lindau (VHL) gene, breast cancer 1. Cyclin-dependent kinase inhibitor 2B. MutL homolog 1. Estrogen receptor. Hypermethylated in cancer 1. Page 12 of 25

Serial No. 10/563,195 Reply to Office Action Mailed: June 20, 2008 Attorney Docket No. 102782.60031US

microvascular endothelial differentiation gene 1, GST-II, O-6-MGMT, O-6-methylguanine-DNA methyltransferase. calcitonin, myo-D₇ Myogenic Differentiation Antigen, urokinase and S100 calcium binding protein A4.

- 27. (Original) A method according to claim 1 wherein the detection of an altered level of alkylated cytosine in the target region of the single stranded DNA is a marker for a disease or condition.
- (Original) A method according to claim 27 wherein the disease or condition is cancer.
- 29. (Original) A method according to claim 28 wherein the cancer is selected from the group consisting of lung cancer, breast cancer, colon cancer, bladder cancer, liver cancer, head and neck tumours, prostate cancer, renal cell tumours, leukemias. Burkitt lymphomas, brain tumours and carcinoma.
- 30. (Original) A method according to claim 1 further comprising diagnosing a disease or condition in the individual on the basis of the presence or the level of alkylated cytosine in the target region of the single stranded DNA.
- 31. (Original) A method according to claim 30 wherein the disease or condition comprises a cancer selected from the group consisting of lung cancer, breast cancer, colon cancer, bladder cancer, liver cancer, head and neck tumours, prostate cancer, renal cell tumours, leukemias, Burkitt lymphomas, brain tumours and carcinoma.

Serial No. 10/563,195 Reply to Office Action Mailed: June 20, 2008 Attorney Docket No. 102782.60031US

32. (Original) A method according to claim 1 wherein the presence or level of the alkylated cytosine is detected to indicate the presence or absence of foetal

DNA.

33. (Original) A method according to claim 1 wherein the presence or level of

the alkylated cytosine is detected for indicating the presence or absence of an

altered gene imprinting state.

34. (Original) A method according to claim 1 wherein the presence or level of

the alkylated cytosine is detected to indicate the presence or absence of a

pathogen or microorganism.

35. (Original) A method according to claim 1 wherein the alkylated cytosine

is methylated cytosine.

36. (Original) A method according to claim 1 wherein the methylated

cytosine is 5- methylcytosine.

37. (Original) A method according to claim 1 wherein the double stranded

DNA is genomic DNA.

38. (Withdrawn) A kit for use in a method of detecting the presence or level

of alkylated cytosine in a sample of genomic or mitochondrial double stranded

Page 15 of 25

Serial No. 10/563,195 Reply to Office Action Mailed: June 20, 2008 Attorney Docket No. 102782.60031US

DNA from an individual as defined in claim 1, wherein the kit comprises one or more reagents for performing the method and instructions for use.